FVII, FVIIa, and downstream markers of extrinsic pathway activation differ by EPCRser219Gly variant in healthy men

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 29, Issue 11, 2009, Pages 1968-1974

  Ireland, Helen A ^a   Cooper, Jackie A ^a   Drenos, Fotios ^a   Acharya, Jayshree ^a   Mitchell, Jacqueline P ^a   Bauer, Ken A ^b   Morrissey, James H ^c   Esnouf, M Peter ^d   Humphries, Stephen E ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Endothelial protein C receptor; Extrinsic coagulation; FIX activation peptide; FVIIa; FX activation peptide; Prothrombin F12

Indexed keywords

BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; ENDOTHELIAL PROTEIN C RECEPTOR; GLYCINE; PROTHROMBIN; SERINE;

ADULT; AMINO ACID SEQUENCE; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; GENE FREQUENCY; GENETIC MARKER; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN POLYMORPHISM;

ANTIGENS, CD; BLOOD COAGULATION; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR VII; FACTOR VIIA; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HETEROZYGOTE; HUMANS; MALE; MEN'S HEALTH; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, CELL SURFACE; REFERENCE VALUES;

EID: 73949130775     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.109.191551     Document Type: Article

References (21)

1. Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost. 2006;32:49-60.
2. Ireland H, Konstantoulas CJ, Cooper JA, Hawe E, Humphries SE, Mather H, Goodall AH, Hogwood J, Juhan-Vague I, Yudkin JS, Di Minno G, Margaglione M, Hamsten A, Miller GJ, Bauer KA, Kim YT, Stearns-Kurosawa DJ, Kurosawa S. EPCR Ser219Gly: elevated sEPCR, F1 + 2, risk for coronary heart disease, and increased sEPCR shedding in vitro. Atherosclerosis. 2005;183:283-292.
3. Qu D, Wang Y, Song Y, Esmon NL, Esmon CT. The Ser219-> Gly dimorphism of the endothelial protein C receptor contributes to the higher soluble protein levels observed in individuals with the A3 haplotype. J Thromb Haemost. 2006;4:229-235.
4. Saposnik B, Reny JL, Gaussem P, Emmerich J, Aiach M, Gandrille S. A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is a candidate risk factor for thrombosis. Blood. 2004;103: 1311-1318.
5. Uitte de Willige S, Van Marion V, Rosendaal FR, Vos HL, de Visser MC, Bertina RM. Haplotypes of the EPCR gene, plasma sEPCR levels and the risk of deep venous thrombosis. J Thromb Haemost. 2004;2:1305-1310.
6. Medina P, Navarro S, Estelles A, Voya A, Woodhams B, Mira Y, Villa P, Migaud-Fressart M, Ferrando F, Aznor J, Bertina RM, Espana F. Contribution of polymorphisms in the endothelial protein C receptor gene to soluble endothelial protein C receptor and circulating activated protein C levels and thrombotic risk. Thromb Haemost. 2004;91:905-911.
7. Preston RJ, Ajzner E, Razzari C, Karageorgi S, Dua S, Dahlback B, Lane DA. Multifunctional specificity of the protein C/activated protein C Gla domain. J Biol Chem. 2006;281:28850-28857.
8. Ghosh S, Pendurthi UR, Esmon CT, Rao LV. Endothelial cell protein C receptor acts as a cellular receptor for factor VIIa on endothelium. J Biol Chem. 2007;282:11849-11857.
9. Lopez-Sagaseta J, Montes R, Puy C, Díez N, Fukudome K, Hermida J. Binding of factor VIIa to the endothelial cell protein C receptor reduces its coagulant activity. J Thromb Haemost. 2007;5:1817-1824.
10. Bauer KA, Kass BL, ten Cate H, Hawiger JJ, Rosenberg RD. Factor IX is activated in vivo by the tissue factor mechanism. Blood. 1990;76: 731-736.
11. Bauer KA, Kass BL, ten Cate H, Bednarek MA, Hawiger JJ, Rosenberg RD. Detection of factor X activation in humans. Blood. 1989;74: 2007-2015.
12. Miller GJ, Ireland HA, Cooper JA, Bauer KA, Morrissey JH, Humphries SE, Esnouf MP. Relationship between markers of activated coagulation, their correlation with inflammation, and association with risk for coronary heart disease (NPHSII). J Thromb Haemost. 2008;6:259-267.
13. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood. 1993;81: 734-744.
14. Ford RP, Esnouf MP, Burgess AI, Sarphie A. An enzyme-linked immunosorbent assay (ELISA) for the measurement of activated factor XII (Hageman factor) in human plasma. J Immunoassay. 1996;17:119-131.
15. Teitel JM, Bauer KA, Lau HK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 +2 fragment and thrombin-antithrombin complex. Blood. 1982;59: 1086-1097.
16. Miller GJ, Bauer KA, Barzegar S, Foley AJ, Mitchell JP, Cooper JA, Rosenberg RD. The effects of quality and timing of venepuncture on markers of blood coagulation in healthy middle-aged men. Thromb Haemost. 1995;73:82-86.
17. Cooper JA, Miller GJ, Bauer KA, Morrissey JH, Meade TW, Howarth DJ, Barzegar S, Mitchell JP, Rosenberg RD. Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation. 2000;102:2816-2822.
18. Saposnik B, Lesteven E, okajczyk A, Esmon CT, Aiach M, Gandrille S. Alternative mRNA is favored by the A3 haplotype of the EPCR gene PROCR and generates a novel soluble form of EPCR in plasma. Blood. 2008;3442-3451.
19. Butenas S, Mann KG. Kinetics of human factor VII activation. Biochemistry. 1996;35:1904-1910.
20. Liaw PC, Neuenschwander PF, Smirnov MD, Esmon CT. Mechanisms by which soluble endothelial cell protein C receptor modulates protein C and activated protein C function. J Biol Chem. 2000;25:5447-5452.
21. Zheng X, Li W, Gu JM, QuD, Ferrell GL, Esmon NL, Esmon CT. Effects of membrane and soluble EPCR on the hemostatic balance and endo-toxemia in mice. Blood. 2007;1:1003-1009.